Home
      Contact Us | Site Map | SEARCH
 
About HDN
About RHOPHYLAC
The Rhophylac Promise
Purity
Rapid Performance
Proven Efficacy
Enhanced Safety
Added Convenience
Professional Resources
Ordering/Reimbursement
Patient Education
Request More Information
Important Saftey Information
Prescribing Information


The Rhophylac® Promise™ of rapid performance

Rapid performance facilitated by intravenous (IV) administration

  • Clearance of 99% of 15 mL RBCs in as little as 12 hours
  • 5 times higher peak performance than intramuscular (IM) administration within first 24 hours1
  • Ideal for emergency and trauma situations
    • For bleeds larger than 15 mL or incompatible transfusion of RBCs or other blood components (eg, platelets)
Rhophylac® Rapid Performance

References:
1. Miescher S, Spycher MO, Amstutz H, et al. A single recombinant anti-RgD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcγRIIA genes and FcγIIIA genes. Blood. 2004;103:4028-4035.



© CSL Behring 2009. The product information on this site is intended for US residents only.

Important Safety Information

Rhophylac® is indicated for suppression of rhesus (Rh) isoimmunization in:

  • Pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with an Rh-incompatible pregnancy, including routine antepartum and postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetric complications, invasive procedures during pregnancy, or obstetric manipulative procedures.
  • Incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells.

For suppression of Rh isommunization, Rhophylac® can be administered IM or IV.

Rhophylac® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

For postpartum use following an Rh-incompatible pregnancy, Rhophylac® should not be given to the newborn infant.

The most common adverse reactions in the suppression of Rh isoimmunization with Rhophylac® are nausea, dizziness, headache, injection-site pain, and malaise.

Please see full prescribing information.